[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620685":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":33,"locations":39,"responsibleParty":176,"collaborators":24,"id":178,"slug":179,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":180,"sex":186,"minAge":187,"maxAge":188,"enrollmentInfo":189,"targetDuration":24,"studyType":192,"phases":193,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":201,"whyStopped":24,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},{"fullName":5,"class":6},"UNICANCER","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Biopsies Liquids +\u002F- Colonoscopy",[13],"Diagnostic Test: INVITRO DIAGNOSTIC TESTS AND COLONOSCOPY",{"label":15,"type":6,"description":16,"interventionNames":17},"Control arm","Colonoscopy each 18 months",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","INVITRO DIAGNOSTIC TESTS AND COLONOSCOPY","The trial compares two strategies: standard follow-up with colonoscopy every 18 months versus an approach combining annual liquid biopsies with a colonoscopy every 36 months",[15,9],null,[26,30],{"name":27,"affiliation":28,"role":29},"Chrystelle Colas, Oncogeneticist","Institut Curie","STUDY_DIRECTOR",{"name":31,"affiliation":32,"role":29},"Toni Seppala, Surgeon","TAMPERE University (Finland)",[34],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Amina Ghorbel, PhD","CONTACT","+33 (0) 6 68 50 20 12","a-ghorbel@unicancer.fr",[40,55,69,84,101,116,131,146,161],{"facility":41,"status":24,"city":42,"state":24,"zip":24,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Klinicki Bolnicki Centar Sestre Milosrdnice Ustanova","Zagreb","Croatia","HR",{"type":46,"coordinates":47},"Point",[48,49],15.97798,45.81444,{"lat":49,"lon":48},[52],{"name":53,"role":36,"phone":24,"phoneExt":24,"email":54},"Iva Kirac","iva.kirac@kbcsm.hr",{"facility":56,"status":24,"city":57,"state":24,"zip":24,"country":58,"countryCode":24,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Masaryk Memorial Cancer Institute","Brno","Czechia",{"type":46,"coordinates":60},[61,62],16.60796,49.19522,{"lat":62,"lon":61},[65],{"name":66,"role":36,"phone":67,"phoneExt":24,"email":68},"Marek Svoboda","+420 543 134 103","msvoboda@mou.cz",{"facility":70,"status":24,"city":71,"state":24,"zip":24,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Tampereen Korkeakoulusäätiö SR","Helsinki","Finland","FI",{"type":46,"coordinates":75},[76,77],24.93545,60.16952,{"lat":77,"lon":76},[80],{"name":81,"role":36,"phone":82,"phoneExt":24,"email":83},"Toni Seppala","+358444722846","toni.seppala@tuni.fi",{"facility":85,"status":24,"city":86,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"GGC Network","Paris","France","FR",{"type":46,"coordinates":90},[91,92],2.3488,48.85341,{"lat":92,"lon":91},[95,98],{"name":96,"role":36,"phone":97,"phoneExt":24,"email":38},"Amina Ghorbel","0668502012",{"name":99,"role":100,"phone":24,"phoneExt":24,"email":24},"Chrystelle Colas","PRINCIPAL_INVESTIGATOR",{"facility":102,"status":24,"city":103,"state":24,"zip":24,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Ist. Tumori di Milano","Milan","Italy","IT",{"type":46,"coordinates":107},[108,109],12.59836,42.78235,{"lat":109,"lon":108},[112],{"name":113,"role":36,"phone":114,"phoneExt":24,"email":115},"Marco Vittellaro","+39 02.2390 2540","marco.vitellaro@istitutotumori.mi.it",{"facility":117,"status":24,"city":118,"state":24,"zip":24,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Pauls Stradins Clinical University Hospital","Riga","Latvia","LV",{"type":46,"coordinates":122},[123,124],24.10589,56.946,{"lat":124,"lon":123},[127],{"name":128,"role":36,"phone":129,"phoneExt":24,"email":130},"Arvids Irmeis","+371 29171604","arvids.irmejs@rsu.lv",{"facility":132,"status":24,"city":133,"state":24,"zip":24,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Erasmus Medisch Centrum Rotterdam","Rotterdam","Netherlands","NL",{"type":46,"coordinates":137},[138,139],4.47917,51.9225,{"lat":139,"lon":138},[142],{"name":143,"role":36,"phone":144,"phoneExt":24,"email":145},"Anja Wagner","0031107036913","a.wagner@erasmusmc.nl",{"facility":147,"status":24,"city":148,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Oslo University Hospital","Oslo","Norway","NO",{"type":46,"coordinates":152},[153,154],10.74609,59.91273,{"lat":154,"lon":153},[157],{"name":158,"role":36,"phone":159,"phoneExt":24,"email":160},"Marte Lie Høivik","+47 924 37 392","m.l.hoivik@medisin.uio.no",{"facility":162,"status":24,"city":163,"state":24,"zip":24,"country":164,"countryCode":165,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"University of Edinburgh","Edinburgh","United Kingdom","UK",{"type":46,"coordinates":167},[168,169],-3.19648,55.95206,{"lat":169,"lon":168},[172],{"name":173,"role":36,"phone":174,"phoneExt":24,"email":175},"Neil Ryan","+1 778 223 9770","neil.ryan@ed.ac.uk",{"type":177,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100620685","study-aiming-to-test-whether-non-invasive-liquid-biopsies-can-safely-reduce-invasive-surveillance-methods-in-lynch-syndrome-100620685",false,"NCT07360834","Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome","Predicting Cancer Onset in Lynch Syndrome by Liquid Biopsies","PREDI-LYNCH","Inclusion Criteria:\n\n1. Participant must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.\n2. Age 35-80\n3. Genetically confirmed class 4-5 (likely pathogenic (LP) or pathogenic (P) variant, respectively) in MLH1, MSH2, MSH6, or EPCAM gene.\n4. The participant should be insurance covered for the financial costs of the standard surveillance and healthcare related to LS, such as affiliated to Social Security System\n\nExclusion Criteria:\n\n1. Previously performed proctocolectomy or equivalent (entire colon and rectum removed)\n2. Active treatment for cancer within 2 years prior to inclusion.\n3. Checkpoint inhibitor therapy within 12 months\n4. Pregnancy\n5. Participants unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.\n6. Persons deprived of their liberty or under protective custody or guardianship.","ALL","35 Years","80 Years",{"count":190,"type":191},2000,"ESTIMATED","INTERVENTIONAL",[194],"NA","Lynch syndrome is an inherited genetic predisposition that increases the risk of developing several types of cancer, particularly colon and rectal cancers (colorectal cancer), as well as cancer of the uterine lining (endometrial cancer). It affects around 1 in 400 people in Europe.\n\nToday, surveillance mainly relies on examinations such as colonoscopy (an examination of the colon using a camera) or gynaecological evaluations, sometimes accompanied by biopsies (the removal of a small tissue sample for microscopic analysis). Although effective, these procedures are invasive and demanding; they can affect quality of life and discourage some individuals from adhering to their recommended surveillance programme.\n\nThe European project PREDI-LYNCH is exploring an additional pathway that is simpler and better tolerated. This project relies on \"liquid biopsies\", meaning tests performed on easily collected samples such as blood, urine, stool, and vaginal swabs for women with a uterus. The PREDI-LYNCH study aims to determine whether these non-invasive tests could enable personalised surveillance and potentially increase the interval between more burdensome procedures, while maintaining a high level of medical safety.",[197],"Lynch Syndrome",[199,200],"Lynch Syndrome, hereditary cancer, MMR deficiency, Liquid biopsies, cancer early detection.","Lynch Syndrome, MMR deficiency, Liquid biopsies","NOT_YET_RECRUITING","2026-01-22",{"date":204,"type":205},"2026-01-23","ACTUAL",{"date":207,"type":191},"2026-04-01",{"date":209,"type":191},"2030-12-01",{"name":5,"class":6},9]